Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV

NCT04444674 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT04444674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04444674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV
Lead sponsor
University of Oxford
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 24, 2020
Completion date
December 31, 2021
Enrollment
2,130 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus